Table 1.
RSE data in LNCaP tumor bearing mice injected with polypeptide-SPIONs, non-targeted SPIONs, and PC3 tumor bearing mice injected with polypeptide-SPIONs.
| Post Injection Time | LNCaP + Polypeptide-SPIONs (Fe3O4 0.240 mg/mL) | LNCaP + Polypeptide-SPIONs (Fe3O4 0.120 mg/mL) | LNCaP + Polypeptide-SPIONs (Fe3O4 0.060 mg/mL) | LNCaP + Polypeptide-SPIONs (Fe3O4 0.030 mg/mL) | LNCaP + Non-Targeted SPIONs (Fe3O4 0.240 mg/mL) | PC3 + Polypeptide-SPIONs (Fe3O4 0.240 mg/mL) | p-Value |
|---|---|---|---|---|---|---|---|
| 2 h | 19.9 ± 3.4 * | 15.7 ± 2.7 * | 11.8 ± 1.6 | 11.3 ± 1.4 | 9.5 ± 2.0 | 8.7 ± 2.2 | 0.000 |
| 6 h | 34.3 ± 3.6 * | 31.1 ± 2.7 * | 23.5 ± 1.4 * | 19.6 ± 0.9 * | 11.9 ± 3.9 | 11.1 ± 3.1 | 0.000 |
| 12 h | 30.9 ± 1.4 * | 30.0 ± 1.4 * | 22.8 ± 1.8 * | 18.5 ± 1.5 * | 12.0 ± 2.0 | 10.4 ± 2.6 | 0.000 |
| p-Value | 0.000 | 0.000 | 0.000 | 0.000 | 0.304 | 0.179 |
* Compared with control groups, p < 0.05. LNCaP, human prostate adenocarcinoma cells derived from the lymph node metastasis; SPION, superparamagnetic iron oxide nanoparticles; PC3, human prostate adenocarcinoma cells derived from the bone metastasis.